KaloBios Pharmaceuticals (KBIO) CEO Pricing Power; Glenview Capital Bets on Humana (HUM)


Shares of KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) soared in early trading Friday to touch the $45.00 mark after the company’s CEO Martin Shkreli said on his Twitter account that he will stop lending his KBIO shares out

KBIO stock closed at $34.83, up $8.20 (or +30.79%), with a total volume of 4,348,357 shares traded during the day, a large increase in activity versus its average volume (3m) of 1,656,860

KaloBios Pharmaceuticals, a biopharmaceutical company, has 4.12M Shares Outstanding, Market Capitalization (intraday) of $143.64M and KBIO stock 52-week range is between $0.44 and $45.82 per share



Humana Inc. (NYSE:HUM) surged $0.51 (or +0.30%) to $168.90 on Friday’s market activity, with a total volume of 627,300 shares traded during the day

Billionaire Larry Robbins’ Glenview Capital Management, LLC disclosed in an SEC filing ( SC 13G ) a 5.05% stake (7,486,029 shares) in the company

Humana recently reported third quarter 2015 non-GAAP earnings of $2.16 per diluted share versus $1.85 in the same period the prior year

Humana, a leading health and well-being company, has 148.22M Shares Outstanding, Market Capitalization (intraday) of $25.04B and HUM stock one-year range is from $137.18 to $219.79 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/